Development and Validation of a New Adherence Scale for Antiseizure Medications [ASASM]
2024

New Scale for Measuring Adherence to Antiseizure Medications

Sample size: 162 publication Evidence: high

Author Information

Author(s): Sarah A. Alotaibi, Noura A. Alrukban, Layla N. Alanizy, Ahmad Saleh, Bshra A. Alsfouk

Primary Institution: Princess Nourah Bint Abdulrahman University

Hypothesis

The study aimed to develop and validate a scale that measures adherence levels to antiseizure medications and identifies reasons for non-adherence.

Conclusion

The ASASM-10 is a reliable and valid tool for evaluating patients' adherence to antiseizure medications.

Supporting Evidence

  • The ASASM-10 showed a good internal consistency with a Cronbach’s alpha of 0.80.
  • The test-retest reliability demonstrated a good correlation of ρ = 0.648.
  • The correlation coefficient demonstrated a positive moderate correlation between ASASM-10 and MARS (ρ = 0.283).
  • The scale was validated by three independent expert judges.

Takeaway

Researchers created a new questionnaire to help doctors understand how well patients are taking their epilepsy medications and why some might not be following their treatment.

Methodology

A cross-sectional study was conducted where patients completed the ASASM-10 and MARS scales to assess adherence.

Potential Biases

Self-report measures may introduce recall bias as participants might not accurately remember their adherence behaviors.

Limitations

The study used a convenience sampling method, which may limit the generalizability of the findings.

Participant Demographics

Participants included 162 patients with epilepsy, aged 18 to 84 years, with a mean age of 34.07 years; 56.2% were male.

Statistical Information

P-Value

< 0.001

Confidence Interval

0.718–0.857

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.3390/jcm13247844

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication